RANKL Immunization Inhibits Prostate Cancer Metastasis by Modulating EMT through a RANKL-Dependent Pathway

The authors used preclinical experimental models to investigate whether an inactive form of receptor activator of nuclear factor kappa-B ligand (RANKL) affected bone metastasis in RANKL-induced prostate cancer.